Additional file 1 of Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
Makaleler > Tam Makale · 2022
Yazarlar: Jovanovic, Dragana M., Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Studnicka, Michael, Tekavec-Trkanjec, Jasna, Littnerová, Simona, Vašáková, Martina
Figshare, Uluslararası, 2022
DOI: 10.6084/m9.figshare.19915356.v1
Özet
Additional file 1: Table S1. Duration of antifibrotic therapies. Table S2. Survival of patients with IPF by number of comorbidities. Table S3. Survival of patients with IPF by number of comorbidities according to antifibrotic therapy. Figure S1. Comorbidities by body system in participating EMPIRE countries. Figure S2. Cardiovascular comorbidities in participating EMPIRE countries. Figure S3. Metabolic and gastrointestinal comorbidities in participating EMPIRE countries. Figure S4. Pulmonary comorbidities in participating EMPIRE countries. Figure S5. Urogenital comorbidities in participating EMPIRE countries. Figure S6. Blood and immunity disorders in participating EMPIRE countries. Figure S7. Other comorbidities in participating EMPIRE countries. Figure S8. Comorbidities in patients with IPF in EMPIRE compared other real-world registries and clinical trials.